Polypharmacy in Elderly Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease
Overview
This study characterizes polypharmacy patterns and clinical risk factors in older adults with metabolic dysfunction–associated steatotic liver disease (MASLD).
Background
Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly prevalent among older adults, often coexisting with multiple chronic conditions. The management of MASLD requires careful consideration of both liver health and age-related issues such as frailty and cognitive impairment. Polypharmacy, defined as the use of five or more medications, poses significant risks, including drug interactions and reduced adherence.
Data Highlights
No numerical data provided in the source material.
Key Findings
Older adults with MASLD often experience polypharmacy, which can complicate treatment.
Polypharmacy is associated with increased risks of falls, frailty, and healthcare utilization.
Management of MASLD requires addressing both liver-specific outcomes and age-related vulnerabilities.
Chronic disease management in this population necessitates a tailored approach to medication management.
Clinical Implications
Clinicians should be aware of the risks associated with polypharmacy in older adults with MASLD.
Conclusion
The findings highlight the complexities of medication management in older adults with MASLD.
